PSI, CURB-65, CALL and BCRSS had a statistically significant relationship with mortality (p
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Introduction This study aimed to determine whether the PSI, CURB-65, CALL and BCRSS had any superiority over each other as a prognostic determinant in patients with COVID-19.
📊
Temel Bulgular & Veri:Material and Method This prospective cohort study included patients over 18 years of age that presented to the emergency department between May 12 and August 12, 2020 and had a positive COVID-19 polymerase chain reaction (PCR) test.
💡
Sonuç & Katkı:PSI, CURB-65, CALL and BCRSS had a statistically significant relationship with mortality (p
🔬Tür:Araştırma Makalesi
📍Kapsam:2020 Verileri
⚙️Değişkenler:PSI · CURB-65 · CALL
Abstract
Introduction This study aimed to determine whether the PSI, CURB-65, CALL and BCRSS had any superiority over each other as a prognostic determinant in patients with COVID-19. Material and Method This prospective cohort study included patients over 18 years of age that presented to the emergency department between May 12 and August 12, 2020 and had a positive COVID-19 polymerase chain reaction (PCR) test. The PSI, CURB-65, CALL and BCRS scores were calculated. SPSS version 22 was used for all statistical analyses. Results A total of 213 patients with a positive COVID-19 PCR result were included in the study. The total 30-day mortality rate was determined as 14.08%. PSI, CURB-65, CALL and BCRSS had a statistically significant relationship with mortality (p
AKÇA, H. Ş., ALGIN, A., ÖZDEMİR, S., SEVİMLİ, H., KOKULU, K., EROĞLU, S. E. (2021). Comparison of the efficacy of PSI, CURB-65, CALL and BCRSS in predicting prognosis and mortality in COVID-19 patients. Journal of Experimental and Clinical Medicine, Cilt: 38 - Sayı: 4, 434–439. https://ajindex.com/articles/677818
Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax 2007;62(3):253-9. Doi: 10.1136/thx.2006.067371. Clinical management of COVID-19. 2020 (Updated 2020 mar 11; cited 2021 Feb 16). Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19.
Duca A, Piva S, Foca E, Latronico N, Rizzi M. Calculated Decisions: Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm.)=6. Emerg Med Pract 2020;16:22(5 Suppl):CD1-CD2. Fan G, Tu C, Zhou F, Liu Z, Wang Y, Song B et al. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. European Respiratory Journal 2020;56:2002113. Doi: 10.1183/13993003.02113-2020.
Garcia Clemente MM, Huertas JH, Fernandez AF, Escosura Munoz C, Enriquez Rodriguez AI, Martinez LP et al. Assessment of risk scores in Covid 19. Int. J. Clin. Pract2020;00:e13705. https://doi.org/10.1111/ijcp.13705.
Grifoni E, Valoriani A, Cei F, Vannucchi V, Moroni F, Pelagatti L et al. The CALL score for predicting outcomes in patients with COVID-19. Clin Infect Dis 2020. Doi:10.1093/cid/ciaa686. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P et al. Prediction for Progression Risk in Patients With COVID19 Pneumonia: The CALL Score. Clinical Infectious disaeses 2020;71(6):1393-9. Doi: 10.1093/cid/ciaa414. Kamran S M, Mirza Z, Moeed H, Naseem A, Hussain M, Fazal Sr I et al. CALL Score and RAS Score as Predictive Models for Coronavirus Disease 2019. Cureus 2020;12(11):e11368. Doi:10.7759/cureus.11368. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82. Lombardy Section Italian Society Infectious And Tropical Diseases. Vademecum for the treatment of people with COVID 19. Edition 2.0, 13 March 2020. Infez Med 2020;28(2):143-52. Menéndez R, Martinez R, Reyes S, Mensa J, Filella X, Marcos MA et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009;64:587-91. Doi:10.1136/thx.2008.105312. Moreno-Pérez O, Andres M, Leon-Ramirez J-M, Sánchez-Payá J, Rodríguez JC, Sánchez R et al. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study, Journal of Autoimmunity 2020;114:102523. https://doi.org/10.1016/j.jaut